Aspirin and prostate cancer prevention

Recent Results in Cancer Research

Volumn 202, Issue , 2014, Pages 93-100

  Bosetti, Cristina ^a   Rosato, Valentina ^a   Gallus, Silvano ^a   La Vecchia, Carlo ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Aspirin; Epidemiology; Neoplasm; Prostate; Risk

Indexed keywords

ACETYLSALICYLIC ACID;

CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; ARTICLE; NONHUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84958544254     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-45195-9_11     Document Type: Review

References (35)

1. Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(5): 518-527
2. Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9(2): 237-249
3. Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C (2006) Aspirin and the risk of prostate cancer. Eur J Cancer Prev 15(1): 43-45
4. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012a) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23(6): 1403-1415
5. Bosetti C, Rosato V, Gallus S, La Vecchia C (2012b) Aspirin and urologic cancer risk: an update. Nat Rev Urol 9(2): 102-110
6. Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23(12): 2840-2855
7. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104(2): 397-401
8. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30(28): 3540-3544
9. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P et al (2009) Aspirin and nonsteroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5): 501-507
10. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12(2): 130-135
11. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL (2011) Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 128(10): 2444-2452
12. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 5(10): 1223-1228
13. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373(9671): 1301-1309
14. Garcia Rodriguez LA, Gonzalez-Perez A (2004) Inverse association between nonsteroidal antiinflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13(4): 649-653
15. Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11(2): 123-134
16. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42(1): 73-78
17. Habel LA, Zhao W, Stanford JL (2002) Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Control 13(5): 427-434
18. Harris RE, Beebe-Donk J, Alshafie GA (2007) Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade (Chapter 9). In: Harris RE (ed) Inflammation in the pathogenesis of chronic diseases. Springer, New York, pp 193-212
19. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8): 608-615
20. Jacobs EJ, Newton CC, Gapstur SM, Thun MJ (2012) Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 104(16): 1208-1217
21. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G (2011) Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 105(8): 1107-1113
22. Liu X, Plummer SJ, Nock NL, Casey G, Witte JS (2006) Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 164(10): 984-989
23. Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7): 1680-1691
24. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D et al (2011) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested casecontrol study. PLoS ONE 6(1):e16412
25. Menezes RJ, Swede H, Niles R, Moysich KB (2006) Regular use of aspirin and prostate cancer risk (United States). Cancer Control 17(3): 251-256
26. Perron L, Bairati I, Moore L, Meyer F (2003) Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 106(3): 409-415
27. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759): 31-41
28. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G et al (2012a) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826): 1602-1612
29. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012b) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826): 1591-1601
30. Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA et al (2010) Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 172(5): 578-590
31. Taketo MM (1998a) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90(20): 1529-1536
32. Taketo MM (1998b) Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 90(21): 1609-1620
33. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4): 252-266
34. Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ (2013) Use of aspirin, but not other nonsteroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 49(4): 938-945
35. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J et al (2000) Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89(3): 589-596